Clinical trial
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- Lead sponsor
- Alnylam Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 22, 2025
- Completion date
- September 23, 2030
- Enrollment
- 11,000 (estimated)
- Sites
- 1,190
Conditions
As the registry lists them; a condition with its own page is linked.
high cardiovascular risk, high risk cardiovascular disease, hypertension